Abbott Laboratories https://www.reuters.com/markets/companies/ABT.N” target=”_blank” rel=”noopener”>(ABT.N) said the market was over-estimating the hit to sales of its glucose monitoring products from growing popularity of weight-loss drugs, adding the treatmen…
Read More
